AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 FEB 6 - (NewsRx.com & NewsRx.net) -- Bioject Medical Technologies, Inc., announced that it has signed an agreement with the Memorial-Sloan Kettering Cancer Center in New York to study the enhanced efficacy for the Biojector 2000 (B-2000) on immune responses to DNA vaccines.
The studies, to be conducted by principal investigators Jedd Wolchok, MD, PhD, and Miguel Perales, MD, will seek to determine the cellular and molecular mechanisms responsible for the enhancement of immunogenicity associated with needle-free injection. In addition, the results will seek to provide greater insight into the immune mechanisms activated by DNA vaccines and permit redesign and optimization of the B2000 for this application. This may ultimately permit realization of the full potential of DNA vaccines for human therapy. Because these vaccines may be powerful agents for combating infectious disease and cancer, they have the potential to provide safe and effective treatment for millions of patients.
"Many preclinical and clinical studies have shown that needle-free injection of DNA vaccines with the B2000 system result in significantly greater immune responses than injection with the needle and syringe," said Jim O'Shea, Bioject. "We look forward to working with Memorial-Sloan Kettering on this and other ongoing collaborations."
...